Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
Cancer
    June 2026
  1. KESSEL AC, Kim H, Brown PD, Lehrer EJ, et al
    Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma.
    Cancer. 2026;132:e70463.
    >> Share

  2. LAWRENCE L
    Stereotactic radiation linked to fewer symptoms in patients with 5-20 brain metastases.
    Cancer. 2026;132:e70405.
    >> Share

    April 2026
  3. ZHANG J, Wang P, Ren Y, Chen L, et al
    Reply to "Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 gliomas".
    Cancer. 2026;132:e70359.
    >> Share

  4. KATKURI SN, Vadhithala V, Kumar S, Verma S, et al
    Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 gliomas.
    Cancer. 2026;132:e70358.
    >> Share

    February 2026
  5. MA Y, Li X, Jiang Y, Xiao L, et al
    The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysis.
    Cancer. 2026;132:e70268.
    >> Share

    January 2026
  6. ZHANG J, Wang D, Liu G, Bu C, et al
    Dynamic signature for the effectiveness of anti-PD-1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial.
    Cancer. 2026;132:e70253.
    >> Share

  7. ZHAO W, Li L, Fu X, Chang Y, et al
    A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.
    Cancer. 2026;132:e70247.
    >> Share

    December 2025
  8. LAWRENCE L
    Diffuse midline gliomas get first FDA-approved drug.
    Cancer. 2025;131:e70146.
    >> Share


  9. Correction to "Determinants of geographic variation in the incidence of adult nonmalignant meningioma in the United States, 2010-2019".
    Cancer. 2025;131:e70206.
    >> Share

  10. ZHANG J, Wang P, Ren Y, Chen L, et al
    Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial.
    Cancer. 2025;131:e70171.
    >> Share

  11. TENG H, Yu J, Pang Y, Yan O, et al
    Long-term recurrence risk and temporal dynamics after resection of intracranial meningiomas: A multicenter cohort study with up to 15 years of follow-up.
    Cancer. 2025;131:e70200.
    >> Share

    November 2025
  12. LAWRENCE L
    ASTRO updates guideline on radiation therapy for grade 4 diffuse gliomas: After maximum safe resection, radiation therapy is the primary modality of therapy for grade 4 diffuse gliomas.
    Cancer. 2025;131:e70089.
    >> Share

    October 2025
  13. WALSH KM
    Counting what counts: Registry completeness and the epidemiology of nonmalignant meningioma.
    Cancer. 2025;131:e70100.
    >> Share

    September 2025
  14. TAN S, He H, Ni J, Guo Y, et al
    Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary ce
    Cancer. 2025;131:e70083.
    >> Share

  15. WITHROW DR, Boyle J, Linet MS, Pittman Ballard CA, et al
    Determinants of geographic variation in the incidence of adult nonmalignant meningioma in the United States, 2010-2019.
    Cancer. 2025;131:e70042.
    >> Share

    August 2025
  16. PERSICO P, Dipasquale A, Losurdo A, Santoro A, et al
    Primary mismatch repair deficiency and Lynch syndrome in adult diffuse gliomas: A call to action.
    Cancer. 2025;131:e70026.
    >> Share

  17. RHA SY, Castanon E, Gill S, Senellart H, et al
    Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.
    Cancer. 2025;131:e70015.
    >> Share

  18. TANG LY, Botros D, Kim AA, Khalafallah AM, et al
    Impact of peri-tumoral resection on survival in primary glioblastoma.
    Cancer. 2025;131:e70016.
    >> Share

    July 2025
  19. SINGH R, Roubil JG, Bowden G, Mathieu D, et al
    Clinical outcomes following stereotactic radiosurgery for brain metastases from sarcoma primaries: An international multicenter analysis.
    Cancer. 2025;131:e35931.
    >> Share

    June 2025

  20. RETRACTION: Phase 1 Study of Concurrent RMP-7 and Carboplatin with Radiotherapy for Children with Newly Diagnosed Brainstem Gliomas.
    Cancer. 2025;131:e35876.
    >> Share

  21. NIERENGARTEN MB
    New standard of care for patients with asymptomatic brain metastases from melanoma.
    Cancer. 2025;131:e35885.
    >> Share

    May 2025
  22. KILICKAP S, Ozguroglu M, Sezer A, Gumus M, et al
    Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 >/=50.
    Cancer. 2025;131:e35864.
    >> Share

    April 2025
  23. BERTUCCI A, Dufour O, Appay R, Harlay V, et al
    Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study.
    Cancer. 2025;131:e35814.
    >> Share

    March 2025
  24. CANNATARO VL, Bracci PM, Taylor JW, McCoy L, et al
    Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters.
    Cancer. 2025;131:e35732.
    >> Share

    November 2024
  25. SINGER S, Schranz M, Hippler M, Kuchen R, et al
    Frequency and clinical associations of common mental disorders in adults with high-grade glioma-A multicenter study.
    Cancer. 2024 Nov 17. doi: 10.1002/cncr.35653.
    >> Share

  26. CHAI TS, Rodgers-Fouche LH, Walls JO, Mattia AR, et al
    Real-world genetic testing outcomes of pan-cancer testing for mismatch repair deficiency.
    Cancer. 2024;130:3888-3893.
    >> Share

    October 2024
  27. AHMAD S, Muhlebner A, Snijders TJ, de Leng WW, et al
    Somatostatin receptor 2A expression in von Hippel-Lindau-related hemangioblastomas.
    Cancer. 2024;130:3473-3479.
    >> Share

    July 2024
  28. ASFAW ZK, Hernandez-Marquez GC, Germano IM
    Patients with glioblastoma: A tale of health care access and genetic ancestry.
    Cancer. 2024 Jul 8. doi: 10.1002/cncr.35470.
    >> Share

    May 2024
  29. HSIEH AL, Bi WL, Ramesh V, Brastianos PK, et al
    Evolving concepts in meningioma management in the era of genomics.
    Cancer. 2024 May 16. doi: 10.1002/cncr.35279.
    >> Share

    February 2024
  30. ZHOU Y, Guo T, Liang F, Wang Z, et al
    Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242.
    >> Share

    January 2024
  31. RANJAN S, Leung D, Ghiaseddin AP, Taylor JW, et al
    Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients.
    Cancer. 2024 Jan 30. doi: 10.1002/cncr.35220.
    >> Share

  32. VAN NOT OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, et al
    BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35178.
    >> Share

    October 2023
  33. LI Y, Cao J, Wang J, Wu W, et al
    Association of the m(6) A reader IGF2BP3 with tumor progression and brain-specific metastasis in breast cancer.
    Cancer. 2023 Oct 20. doi: 10.1002/cncr.35048.
    >> Share

  34. PAPINI C, Willard VW, Gajjar A, Merchant TE, et al
    Social cognition and adjustment in adult survivors of pediatric central nervous system tumors.
    Cancer. 2023;129:3064-3075.
    >> Share

    September 2023
  35. RIEDINGER CJ, Esnakula A, Haight PJ, Suarez AA, et al
    Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers.
    Cancer. 2023 Sep 26. doi: 10.1002/cncr.35030.
    >> Share

  36. LU S, Guo X, Li Y, Liu H, et al
    Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis.
    Cancer. 2023 Sep 8. doi: 10.1002/cncr.35003.
    >> Share

    August 2023
  37. HEFFERNAN AE, Wu Y, Benz LS, Verhaak RGW, et al
    Quality of life after surgery for lower grade gliomas.
    Cancer. 2023 Aug 20. doi: 10.1002/cncr.34980.
    >> Share

  38. MAAS A, Maurice-Stam H, Kremer LCM, van der Aa-van Delden A, et al
    Psychosocial outcomes in long-term Dutch adult survivors of childhood cancer: The DCCSS-LATER 2 psycho-oncology study.
    Cancer. 2023;129:2553-2567.
    >> Share

  39. BAIREY O, Taliansky A, Glik A, Amiel A, et al
    A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
    Cancer. 2023 Aug 12. doi: 10.1002/cncr.34985.
    >> Share

    June 2023
  40. BALIGA S, Palmer JD, Yock TI
    Reply to "Is the hippocampus-sparing attempt really reasonable within the current technological possibilities?".
    Cancer. 2023;129:1779-1780.
    >> Share

  41. ELMALI A, Mohammadipour S, Yazici G
    Is the hippocampus-sparing attempt really reasonable within the current technological possibilities?
    Cancer. 2023;129:1777-1778.
    >> Share

    May 2023
  42. MULLER BARK J, Trevisan Franca de Lima L, Zhang X, Broszczak D, et al
    Proteome profiling of salivary small extracellular vesicles in glioblastoma patients.
    Cancer. 2023 May 31. doi: 10.1002/cncr.34888.
    >> Share

  43. ESTEVEZ-ORDONEZ D, Abdelrashid M, Coffee E, Laskay NMB, et al
    Racial and socioeconomic disparities in glioblastoma outcomes: A single-center, retrospective cohort study.
    Cancer. 2023 May 28. doi: 10.1002/cncr.34881.
    >> Share

  44. NEFF C, Price M, Cioffi G, Kruchko C, et al
    Complete prevalence of primary malignant and non-malignant brain tumors in comparison to other cancers in the United States.
    Cancer. 2023 May 18. doi: 10.1002/cncr.34837.
    >> Share

  45. BARDEN MM, Omuro AM
    Top advances of the year: Neuro-oncology.
    Cancer. 2023;129:1467-1472.
    >> Share

    April 2023
  46. COLE KA, Ijaz H, Surrey LF, Santi M, et al
    Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
    Cancer. 2023 Apr 20. doi: 10.1002/cncr.34786.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016